Cerevance Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 45

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $20M

  • Investors
  • 14

Cerevance General Information

Description

Developer of novel therapeutics intended for new medicine formulation for central nervous system diseases. The company's therapeutics applies its technology to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Contact Information

Formerly Known As
Takeda Cambridge Neuroscience
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • One Marina Park Drive
  • Suite 1410
  • Boston, MA 02210
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • One Marina Park Drive
  • Suite 1410
  • Boston, MA 02210
  • United States

Cerevance Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cerevance Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series C) 23-Apr-2026 $20M Completed Clinical Trials - Phase 3
6. Secondary Transaction - Private Completed Clinical Trials - Phase 3
5. Later Stage VC (Series B) 13-Mar-2024 Completed Clinical Trials - Phase 3
4. Early Stage VC 21-Feb-2018 Completed Clinical Trials - General
3. Early Stage VC 03-May-2017 Completed Clinical Trials - General
2. Early Stage VC (Series A) 02-Dec-2016 $21.5M $36M Completed Clinical Trials - General
1. Early Stage VC $14.5M $14.5M Completed Clinical Trials - General
To view Cerevance’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Cerevance Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics intended for new medicine formulation for central nervous system diseases. The company's
Drug Discovery
Boston, MA
45 As of 2025

Broomfield, CO
 

Framingham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cerevance Competitors (42)

One of Cerevance’s 42 competitors is Cerecin, a Venture Capital-Backed company based in Broomfield, CO.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cerecin Venture Capital-Backed Broomfield, CO
Alzheon Venture Capital-Backed Framingham, MA
Cognition Therapeutics Formerly VC-backed New York, NY
Fauna Bio Venture Capital-Backed Emeryville, CA
CervoMed Formerly VC-backed Boston, MA
You’re viewing 5 of 42 competitors. Get the full list »

Cerevance Patents

Cerevance Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202506133-D0 Novel compounds Pending 24-Apr-2025
GB-202502494-D0 Novel treatment Pending 20-Feb-2025
WO-2026176180-A1 Novel treatment Pending 20-Feb-2025
WO-2026150221-A1 Combination of cvn-766 and a glp-1 receptor agonist for use in the treatment of obesity and overweight Pending 13-Jan-2025
WO-2025229336-A1 Novel process of preparing a trisubstituted pyrazine derivative Pending 01-May-2024 C07D241/20
To view Cerevance’s complete patent history, request access »

Cerevance Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cerevance Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Agent Capital Venture Capital Minority
Casdin Capital Venture Capital Minority
Dolby Family Ventures Venture Capital Minority
Double Point Ventures Venture Capital Minority
Foresite Capital Growth/Expansion Minority
You’re viewing 5 of 14 investors. Get the full list »

Cerevance FAQs

  • When was Cerevance founded?

    Cerevance was founded in 2016.

  • Where is Cerevance headquartered?

    Cerevance is headquartered in Boston, MA.

  • What is the size of Cerevance?

    Cerevance has 45 total employees.

  • What industry is Cerevance in?

    Cerevance’s primary industry is Drug Discovery.

  • Is Cerevance a private or public company?

    Cerevance is a Private company.

  • What is Cerevance’s current revenue?

    The current revenue for Cerevance is .

  • How much funding has Cerevance raised over time?

    Cerevance has raised $234M.

  • Who are Cerevance’s investors?

    Agent Capital, Casdin Capital, Dolby Family Ventures, Double Point Ventures, and Foresite Capital are 5 of 14 investors who have invested in Cerevance.

  • Who are Cerevance’s competitors?

    Cerecin, Alzheon, Cognition Therapeutics, Fauna Bio, and CervoMed are some of the 42 competitors of Cerevance.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process